The Food and Drug Administration today announced the expansion of its emergency use authorization for Pfizer’s COVID-19 vaccine to include adolescents ages 12 to 15. The expansion comes ahead of Wednesday’s convening of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, whose recommendation will be an important part of CDC’s decision on whether to recommend vaccination for that age group.
 
The FDA has updated the Pfizer vaccine-specific Fact Sheets for Healthcare Providers Administering the Vaccine (Vaccination Providers) and for Recipients and Caregivers with information to reflect the use of the vaccine in the adolescent population.
 

Related News Articles

Headline
The Health Resources and Services Administration today awarded 14 organizations grants to hire people to support COVID-19 vaccination and outreach in…
Headline
The Food and Drug Administration Friday authorized for emergency use two batches of drug substance manufactured for the Janssen (Johnson & Johnson)…
Headline
Novavax today announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.…
Headline
The Food and Drug Administration yesterday warned health care providers and the public not to use an antigen test for COVID-19 made by Innova Medical Group and…
Headline
The Centers for Disease Control and Prevention is asking jurisdictions to distribute portions of their COVID-19 vaccine allocations to enable administration at…
Headline
Johnson & Johnson today said the Food and Drug Administration agreed to extend the expiration date for its COVID-19 vaccine by six weeks. The move means…